Malaria is among the most serious infectious diseases affecting humans, accounting for approximately half a million deaths each year 1 . Plasmodium falciparum causes most life-threatening cases of malaria. Acquired immunity to malaria is inefficient, even after repeated exposure to P. falciparum 2 , but the immune regulatory mechanisms used by P. falciparum remain largely unknown. Here we show that P. falciparum uses immune inhibitory receptors to achieve immune evasion. RIFIN proteins are products of a polymorphic multigene family comprising approximately 150-200 genes per parasite genome 3 that are expressed on the surface of infected erythrocytes. We found that a subset of RIFINs binds to either leucocyte immunoglobulin-like receptor B1 (LILRB1) or leucocyte-associated immunoglobulin-like receptor 1 (LAIR1). LILRB1-binding RIFINs inhibit activation of LILRB1-expressing B cells and natural killer (NK) cells. Furthermore, P. falciparuminfected erythrocytes isolated from patients with severe malaria were more likely to interact with LILRB1 than erythrocytes from patients with non-severe malaria, although an extended study with larger sample sizes is required to confirm this finding. Our results suggest that P. falciparum has acquired multiple RIFINs to evade the host immune system by targeting immune inhibitory receptors.
responses. We therefore analysed the binding of 13 human inhibitory receptors fused to Fc antibody fragments to erythrocytes infected with the P. falciparum laboratory strain 3D7 or with P. falciparum isolated from patients with malaria. In this screen, leucocyte immunoglobulinlike receptor B1 (LILRB1) was the only receptor that exhibited detectable increased binding to a small fraction of IEs (Extended Data Fig. 1 ).
Next, we investigated whether LILRB1 bound to erythrocytes infected with P. falciparum isolates acquired from seven Thai patients with malaria. We found that LILRB1 bound a large fraction (77%) of IEs from patient 6 and small fractions from patients 1 (32%) and 4 (15%) ( Fig. 1a and Extended Data Fig. 2a ). LILRB1, also known as ILT2, CD85j or LIR-1, is an inhibitory receptor of the LILR family, which are expressed on diverse immune cells and encoded by genes within the leucocyte receptor complex (LRC) region 11 . LILRB1, which recognizes MHC class I molecules 12 , binds to the MHC class I-like UL18 13 encoded by human cytomegalovirus, suggesting that the LILR family coevolved with microbial pathogens 11, 14 . Binding of LILRB1 to IEs was primarily observed during the middle trophozoite and schizont stages of P. falciparum development ( Fig. 1b and Extended Data Fig. 2b ). LILRB1 bound to subpopulations of IEs infected with four P. falciparum laboratory strains ( Fig. 1c and Extended Data Fig. 2c ). Erythrocytes do not express MHC class I molecules, indicating that a parasite-derived molecule served as an LILRB1 ligand.
The P. falciparum genome does not encode an MHC class I-like gene 15 . Thus, to identify putative LILRB1 ligands on IEs, we took advantage of the 3D7 strain of parasites, for which whole-genome sequence data are available. LILRB1-Fc bound to a small proportion of 3D7 IEs. We therefore enriched 3D7 IEs for LILRB1 binding using cell sorting and subsequently subcloned 3D7 parasites using limiting dilution to obtain LILRB1-binding (F2) and non-binding (D11) parasite clones (Fig. 1d ). The proportions of LILRB1-binding IEs (F2) decreased during passage after cloning (Extended Data Fig. 2e ), suggesting that the expression of putative LILRB1 ligands was regulated by transcriptional switching between members of a P. falciparum multigene family. To identify putative LILRB1 ligands on IEs, we conducted mass spectrometric analyses of proteins that co-precipitated with LILRB1-Fc from 3D7 F2 and D11 clones (Extended Data Fig. 3a ). In two independent experiments, only one peptide (FHEYDER), which had a sequence that matched RIFIN sequences, was specific to F2 immunoprecipitates (Extended Data Fig. 3b, c and Supplementary Table 1 ). RIFINs are encoded by 150-200 rif genes per parasite genome 3 . The FHEYDER sequence is shared among 36 RIFINs in the 3D7 genome. Therefore, we cloned these rif genes to assess RIFIN binding to LILRB1. We cloned 25 and 6 rif genes with and without the FHEYDER sequence, respectively. Erythrocytes infected with 3D7 parasites transfected with each rif gene (Supplementary Table 2 ) were screened for binding to LILRB1-Fc (Extended Data Fig. 4a ). IEs transfected with RIFINs #1 and #2 (PF3D7_1254800 and PF3D7_0223100) bound strongly to LILRB1-Fc, whereas IEs transfected with RIFINs #3-5 (PF3D7_0500400, PF3D7_1000500 and PF3D7_1254200) did not ( Fig. 2a and Extended Data Fig. 4a ). The presence of the FHEYDER sequence in the transfected RIFINs was not associated with LILRB1-Fc binding ( Fig. 2b and Extended Data Fig. 4a ). The gene expression of RIFINs #3-5, which did not bind to LILRB1-Fc (LILRB1 − RIFINs), was similar to or higher than that of RIFINs #1 and #2, which did bind to LILRB1-Fc (LILRB1 + RIFINs) (Extended Data Fig. 5a ). To validate these findings, we generated transgenic parasites expressing C-terminally His-tagged RIFINs #1, #2 or #5 (Extended Data Fig. 5b ). Again, IEs transfected with RIFINs #1 and #2, but not RIFIN #5, bound to LILRB1-Fc (Extended Data Fig. 5c ). These results indicate that a subset of RIFINs on IEs acts as LILRB1 ligands.
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The extracellular domain of RIFINs comprises a relatively conserved N-terminal region containing the FHEYDER sequence and a highly variable C-terminal region (Fig. 2b ). LILRB1-Fc bound to the variable rather than the conserved region of LILRB1 + RIFIN #1 expressed on 293T cells (Fig. 2c ). Furthermore, recombinant LILRB1 + RIFIN #1 protein, but not LILRB1 − RIFIN #5, bound to LILRB1 expressed on transfected 293T cells ( Fig. 2d and Extended Data Fig. 6 ). These results indicate that RIFINs interact directly with LILRB1 through specific amino acids or conformations within their variable region.
The LILR family comprises five activating, five inhibitory and one soluble form. LILRB1 shares more than 80% sequence identity with the activating LILRA2, which recognizes microbially cleaved immunoglobulins 14 RIFIN #1 expressed on 293T cells (Extended Data Fig. 7a ). Similarly, LILRB1 was the only LILR family member that bound to erythrocytes infected with RIFIN #1-transgenic parasites (Extended Data Fig. 7b ).
No LILR bound to erythrocytes infected with RIFIN #5-transgenic parasites (Extended Data Fig. 7b ). These data suggest that certain RIFINs evolved to interact specifically with LILRB1. The natural ligands for LILRB1 are HLA class I molecules 12 . However, a search using Phyre2 indicated that neither LILRB1 + RIFINs nor LILRB1 − RIFINs share amino acid sequence similarities or predicted structural homology with HLA class I molecules. Furthermore, we could not identify amino acid sequence motifs characteristic of LILRB1 + RIFINs. Similar to the recent determination of the protein structure of PfEMP1-host receptor interactions 16, 17 , solving the structure of the LILRB1-RIFIN interaction may clarify molecular constraints that confer receptor-binding specificity and antigenic diversity on RIFINs. LAIR1 is a gene within the LRC that encodes an inhibitory receptor for collagens, similar to LILRB1, suggesting that these genes are evolutionarily related 18 . Unique antibodies isolated from individuals living in a malaria-endemic region contained a mutated LAIR1 insert that bound to RIFIN #6 (PF3D7_1400600) and RIFIN #7 (PF3D7_1040300), whereas binding of wild-type LAIR1 to these RIFINs was undetectable or weak 19, 20 . Three amino acid substitutions in the mutated LAIR1 (T67L/N69S/A77T) are responsible for its increased binding to RIFINs. Consistent with previous observations 19, 20 , mutated LAIR1 (T67L/ N69S/A77T)-Fc bound to IEs from parasites transfected with RIFINs #6 and #7, but wild-type LAIR1-Fc did not (Extended Data Fig. 8a ). However, when analysing the binding of wild-type LAIR1 to IEs from 15 RIFIN-transgenic parasite lines (Extended Data Fig. 4b ), we found that LAIR1-Fc bound to IEs from parasites transfected with LILRB1 − RIFIN #8 (PF3D7_1101100) ( Fig. 2a ). Moreover, wild-type LAIR1-Fc bound 5-78% of erythrocytes infected with parasites from Thai patients with malaria (Extended Data Fig. 8b ).
When IE binding of both LILRB1-Fc and LAIR1-Fc was analysed using parasites isolated from three patients, IEs derived from patient 1 predominantly bound to both LILRB1-Fc and LAIR1-Fc, whereas IEs derived from patient 5 or patient 6 predominantly bound to LAIR1-Fc or LILRB1-Fc, respectively (Extended Data Fig. 8c ). Similar to LILRB1 + RIFINs, structural homology to natural ligands for LAIR1 (collagens) 21 was not predicted from our analysis of the LAIR1-binding (LAIR1 + ) RIFIN #8 sequence. Consistent with previous studies of RIFIN expression 22 , these results suggest that RIFINs are expressed on the IE cell surface in a variegated manner and that P. falciparum evades immune attack through the interaction of RIFINs with various inhibitory receptors.
Next, we investigated whether RIFINs induced LILRB1-or LAIR1mediated cell signalling using the nuclear factor of activated T cells (NFAT)-GFP reporter system, in which GFP expression is induced upon ligand interaction with LILRB1 or LAIR1 14, 23, 24 (Fig. 3a) . When LILRB1-reporter cells were co-cultured with immobilized recombinant RIFINs, the cells were activated and GFP expression was induced by LILRB1 + RIFIN #1 but not by LILRB1 − RIFIN #5 (Fig. 3b ). Moreover, when LILRB1-reporter cells were co-cultured with erythrocytes infected with RIFIN-transgenic parasites, LILRB1-reporter cells were activated by IEs expressing LILRB1 + RIFIN #1 but not by IEs expressing LILRB1 − RIFIN #4 ( Fig. 3c and Extended Data Fig. 2d ). By contrast, IEs expressing LAIR1 + RIFIN #8 did not significantly stimulate LAIR1reporter cells, whereas collagen, a host ligand for LAIR1, significantly stimulated the reporter cells (Extended Data Fig. 9a ). Similarly, IEs derived from patient 1 and LAIR1 + IEs enriched from patient 4 IEs using cell sorting did not significantly stimulate LAIR1-reporter cells (Extended Data Fig. 9b, c) . These results suggest that the LAIR1-RIFIN interaction was not sufficiently strong to deliver inhibitory signals that were detectable in this assay. However, the LAIR1-RIFIN interaction may transduce an inhibitory signal via LAIR1 in other in vivo situations.
LILRB1 is expressed on various types of immune cells, including T cells, B cells, NK cells and monocytes. LILRB1 expressed by primary human B cells is involved in suppressing B cell responses 25 . We therefore examined the effects of RIFINs on B cells expressing LILRB1 (Fig. 3d ). IEs expressing LILRB1 + RIFIN #1, but not LILRB1 − RIFIN #4, inhibited IE-induced immunoglobulin M (IgM) production 26 by primary human B cells in preparations of peripheral blood mononuclear cells (PBMCs) (Fig. 3e) . Similarly, Chinese hamster ovary (CHO) cells expressing LILRB1 + RIFIN #1, but not LILRB1 − RIFIN #3, inhibited IgM production by PBMCs ( Fig. 3f ). We next investigated the effects of LILRB1 + RIFIN #1 and LILRB1 − RIFIN #5 on the cytolytic function of an LILRB1-expressing human NK cell line, NKL (Extended Data Fig. 9d ). K562 cells, often used as targets for NK cells, stably transfected with LILRB1 + RIFIN #1 were more resistant to NK-mediated killing than parental or K562 cells stably transfected with LILRB1 − RIFIN #5, suggesting that the NK cell response is downregulated by the LILRB1-RIFIN interaction (Extended Data Fig. 9e, f) . These results indicate that malaria parasites use RIFINs to downregulate immune cells and impair anti-malarial immunity.
These data led us to hypothesize that binding of IEs to LILRB1 contributes to parasite survival during infection and might be associated with the development of severe malaria. To evaluate this hypothesis, we analysed binding of LILRB1 to IEs from Tanzanian patients with t r a n s g e n ic malaria. A significantly (P = 0.013) higher number of IEs from patients with severe malaria (cerebral malaria or severe malarial anaemia) bound to recombinant LILRB1-Fc compared with IEs from patients without these severe forms of malaria (Fig. 4a ). The median number of IEs from patients without severe malaria that bound to LILRB1-Fc was close to zero. This finding indicates that IEs from patients with severe malaria more often express LILRB1 + RIFINs and that LILRB1-binding IEs contribute to the pathogenesis of severe malaria. However, the sample size in this study was small (severe malaria, n = 9; non-severe malaria, n = 30), and further studies are required to clarify LILRB1's role in the pathogenesis of malaria.
Variation in P. falciparum surface antigens in vivo is governed by the host's immune status 27, 28 . In areas with high P. falciparum transmission, immunity to severe malaria is acquired early in life and before the acquisition of clinical immunity 2 . Thus, antibodies against RIFIN subsets associated with severe malaria may be acquired early and before antibodies to other RIFINs. Therefore, we analysed IgG reactivity with recombinant proteins derived from the RIFIN-variable regions of LILRB1 + RIFIN #1 and LILRB1 − RIFIN #5 in plasma from 222 Tanzanian individuals. IgG acquisition was similar for the two RIFINs and showed a very early and marked increase in the proportion of individuals responding to the RIFINs one year after birth, plateauing thereafter, as previously reported for another RIFIN 29 (Extended Data Fig. 10 ). Although antibody acquisition was similar for the two RIFINs, the rapid acquisition of antibodies suggests that RIFINs play an active role in early infections and may serve as important targets of protective immunity.
RIFIN-binding antibodies with LAIR1 inserted into their variable regions 19 appear to be produced in response to P. falciparum infection 20 , potentially to inhibit the interaction between RIFINs and native LAIR1. This finding and the data presented here suggest that RIFINs evolved to bind inhibitory receptors and thereby facilitate escape from the host immune system (Fig. 4b ). RIFINs are unique to P. falciparum but belong to the Plasmodium interspersed repeats (pir) protein superfamily, which is encoded by multigene families present in all human-and rodent-specific species of Plasmodium (for example, vir of P. vivax, kir of P. knowlesi and cir, bir and yir of rodent malaria parasites 30 ). Studies of the interactions between immune receptors and these polymorphic protein families may further identify crucial host-parasite interactions in the regulation of malarial infections. Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests; details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to H.A. (arase@biken.osaka-u.ac.jp).
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The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Cells. Human embryonic kidney 293T and CHO cells were obtained from and authenticated by the RIKEN Cell Bank. NKL cells 31 were a gift from L. L. Lanier (University of California, San Francisco). The K562 cell line was obtained from the Cell Resource Centre for Biomedical Research, Institute of Development, Ageing and Cancer, Tohoku University. PBMCs were separated from the blood of healthy donors using Ficoll density gradient centrifugation (GE Healthcare). Each cell line was tested regularly for mycoplasma contamination using PCR. Collection of P. falciparum parasites from Thai patients with malaria. All clinical P. falciparum isolates were acquired from patients living in the Mae Sariang district, Mae Hong Son Province in Thailand according to the ethical guidelines described below. Clonal parasite lines were established from field-isolated parasites using limiting dilution. All parasite strains were cultivated with human erythrocytes (type O blood, haematocrit (Ht) 2%, the Japanese Red Cross Blood Centre) in complete medium, which consisted of RPMI-1640 medium containing 20% AlbuMAX I (Life Technologies), 25 mM HEPES, 0.225% sodium bicarbonate and 0.38 mM hypoxanthine supplemented with 10 μg ml −1 gentamicin. Strains were incubated in an atmosphere containing 90% N 2 , 5% CO 2 and 5% O 2 . P. falciparum culture. The P. falciparum strains 3D7 32 , CDC1 33 , K1 34 , FCR3 34 and Dd2 32 and parasites from Thai patients were cultured with human erythrocytes in RPMI-1640 containing 10% human serum. Transgenic parasites were maintained in RPMI-1640 containing 10% human serum and 25 ng/ml pyrimethamine (Sigma-Aldrich). Parasites were synchronized at the ring stage using 5% d-sorbitol, and trophozoite-and schizont-stage parasites were enriched using Percoll density gradient centrifugation (GE Healthcare). Parasite cultures were tested routinely for mycoplasma contamination using PCR. Cloning of P. falciparum 3D7 parasites. The 3D7 parasite cultures enriched for LILRB1-binding IEs were generated by sorting cells that bound to LILRB1-Fc fusion protein pre-mixed with anti-IgG Fc-APC antibodies. These enriched IEs were then subjected to limiting dilution to obtain a single clone. In brief, the enriched parasites were synchronized at the ring stage using 5% d-sorbitol. After 48 h, parasites at the late schizont stage were purified using 63% (v/v) Percoll (Amersham Pharmacia Biotech) density gradient centrifugation. The parasites in culture medium (10% O-type human serum in RPMI 1640; GIBCO BRL) were mixed with freshly prepared human erythrocytes and cultured in a T-75 flask (parasitaemia, 1%; haematocrit, 2%). One hour after incubation at 37 °C in an atmosphere containing 5% CO 2 , 5% O 2 and 90% N 2 (CO 2 -O 2 -N 2 incubator BNP-110, TABAI ESPEC Corp), the cap of the flask was tightly sealed, and the flask was shaken on an orbital shaker at 100 r.p.m. to avoid multiple infections of a single erythrocyte. The parasite stage was monitored every 2 h using Giemsa staining, and after most parasites proceeded to the ring stage, the parasite culture was diluted using fresh culture medium with erythrocytes (3% haematocrit). The diluted parasites (0.5 parasites per 0.2 ml) were plated in 96-well flat bottom plates, and 50% of the culture medium was changed every 48 h. After 2 weeks in culture, parasites were detected in approximately 20 wells per plate, and LILRB1-binding positive and negative wells were screened using flow cytometric analysis. LILRB1 + F2 and LILRB1 − D11 clones were obtained using this procedure. Plasmids. Plasmids for paired immunoglobulin-like type 2 receptor (PILR)α-Fc, CD200R-Fc and LILR-Fc fusion protein production were constructed as previously described 14, 35, 36 . Plasmids for LAIR1 (GenBank: AF013249.1, amino acid residues 23-165), KIR2DL1* 003 (amino acid residues 22-245), KIR2DL2* 001 (amino acid residues 22-245), KIR2DL3* 001 (amino acid residues 22-245), KIR2DL4* 001 (amino acid residues 24-240), KIR2DL5* 001 (amino acid residues 22-239) and KIR3DL1* 001 (amino acid residues 22-339) were constructed in the same manner. Fc fusion proteins of these inhibitory receptors were used for analyses of binding to IEs. A plasmid encoding a mutated LAIR1 (T67L/ N69S/A77T) Fc fusion protein was generated using site-directed mutagenesis of the wild-type LAIR1 and a QuikChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies). To produce a biotinylated LILR-Fc fusion protein, C-terminally AviTagged-LILR-Fc plasmids were constructed via insertion into a pCAGGS expression vector. To generate transgenic parasites, full-length genome sequence of RIFINs, including an intron, were obtained using PCR amplification of the 3D7 genome with primer sets ( Supplementary Table 3 ) and inserted into the PfCEN5 expression vector. Each RIFIN-PfCEN5 expression vector was cloned in Escherichia coli and subjected to Sanger sequencing (Supplementary Sequence Chromatogram). Each rif sequence was compared with the 3D7 genome version 3 (release 32, PlasmoDB, http://plasmodb.org). For RIFINs that were unexpectedly cloned because of sequence similarity in their 5′ and 3′ termini, nucleic acid sequences of primer annealing sites were replaced with primer sequences. However, sequences of conserved and variable regions were identical to the reference sequences. Silent and missense mutations in the cloned RIFINs are summarized in Supplementary Table 2 . As a mock control, we used a PfCEN5 expression vector containing GFP. To confirm that the first intron in the rif transgenes was correctly spliced out of their IE transcripts, cDNAs synthesized from RIFIN #1-5 and #8 transgenic IEs were amplified using PCR with the primers 5′ -TTATCCTTATTTTTTAATAACTGCC-3′ and 5′ -GTTCGTGGCATTCCAC-3′ , followed by direct sequencing of the amplicons. As shown in the Supplementary Sequence Chromatogram, the first intron was correctly spliced out of the transcripts, resulting in in-frame transcripts. A structural homology search of RIFINs was conducted using Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2). C-terminally His-tagged RIFINs #1, #2 and #5 were constructed using these cloned RIFIN-PfCEN5 expression vectors. Full-length RIFIN #6 (PF3D7_1400600) and RIFIN #7 (PF3D7_1040300) were synthesized by IDT and GenScript, respectively, and cloned into the PfCEN5 expression vector. For cell surface expression of RIFINs on 293T and CHO cells, the extracellular domains of RIFIN #1 (amino acid residues 166-275) and RIFIN #3 (amino acid residues 166-331) linked to the transmembrane and cytoplasmic regions of PILRα (amino acid residues 196-256) 37 were cloned into a pME18s expression vector 37 . N-terminal conserved and C-terminal variable regions of RIFIN #1 corresponding to amino acid residues 39-139 and 166-275, respectively, were expressed with the transmembrane and cytoplasmic regions of PILRα , respectively, using the pME18s expression vector. To generate recombinant RIFIN #1 (amino acid residues 166-275) and #5 (amino acid residues 168-309) using a wheat germ cell-free protein expression system, C-terminally Histagged RIFINs were constructed by synthesizing codon-optimized versions of the rif gene (https://www.eurofinsgenomics.com/en/home.aspx), followed by insertion into a pEU-E01 expression vector (CellFree Sciences). To generate recombinant RIFIN #1 (amino acid residues 166-275) and #5 (amino acid residues 168-309) in E. coli, N-terminally His-tagged RIFINs were constructed by synthesizing codonoptimized versions of rif genes (IDT), followed by insertion into the pET-15b vector (N-terminally His-tagged cassette). Transfection. The transient transfection of plasmids into 293T and CHO cells was conducted using PEI Max (Polysciences). For 293T cell surface expression, plasmids encoding target molecules and GFP were used to co-transfect 293T cells, and GFP-positive cells were analysed as previously described 38 . To express RIFINs on the cell surface of CHO cells, plasmids encoding fusion proteins comprising RIFINs and the transmembrane and cytoplasmic domains of mouse PILRα or mock (human melanoma differentiation-associated protein 5 (MDA5)) were used to co-transfect CD8 into CHO cells. Stable transfectants of K562-RIFIN #1 (amino acid residues 166-275) and #5 (amino acid residues 168-309) were generated using retrovirus-mediated transduction with the pMxs retroviral expression vector and PLAT-E retroviral packaging cells transfected with an amphotropic envelope as previously described 39 . Flow cytometry. The binding of human receptor-Fc fusion proteins to IEs was examined by staining IEs with Fc fusion proteins premixed with an allophycocyanin (APC)-conjugated anti-human IgG Fc antibody (109-136-098, Jackson ImmunoResearch Laboratories). For the PILRα -Fc fusion protein, cells were mixed with PILRα -Fc followed by APC conjugated anti-human IgG Fc antibody to decrease non-specific staining. For double staining of IEs with LAIR1-Fc and LILRB1-Fc fusion proteins, LAIR1-Fc or LILRB1-Fc was mixed with an APC-conjugated anti-human IgG Fc antibody or an phycoerythrin (PE)conjugated anti-human IgG Fc antibody (109-116-098, Jackson ImmunoResearch Laboratories), respectively, followed by blocking these complexes with purified human IgG (Cappel). Thereafter, IEs were stained with these complexes. The LILRA2-Fc fusion protein was used as a control. The binding of His-tagged recombinant RIFINs to LILR-transfected 293T cells was analysed by staining with recombinant His-tagged RIFINs, followed by detection with an anti-His antibody (clone 28-75; WAKO) or an anti-DYKDDDDK (Flag) antibody (clone L5; Biolegend). Nuclei of IEs were stained using Vybrant Green (Thermo). Populations of IEs or reporter cells were gated using FSC and SSC parameters (Supplementary Gating Strategy for Flow Cytometry Analysis). Flow cytometric analyses were conducted using BD FACSCalibur, LSR II and FACSVerse flow cytometers (BD Biosciences). Data were analysed using FlowJo software (FlowJo). Preparation of infected red cell ghosts. P. falciparum-infected red cells were incubated for 15 min at 4 °C in 40 volumes of hypotonic solution (RPMI-1640 diluted fivefold in water). Ghost cells were collected by centrifugation at 15,000 r.p.m. for 15 min and washed three times with a hypotonic solution. Biotinylation of LILRB1-Fc protein and immunoprecipitation. Purified AviTag-LILRB1-Fc was biotinylated using BirA biotin-protein ligase (Avidity) (Extended Data Fig. 3a ). Red-cell ghosts obtained from erythrocytes infected with the LILRB1 + F2 or LILRB1 − D11 clones at the schizont stage were incubated with biotinylated LILRB1-Fc fusion protein and subsequently treated with 0.25 mM 3,3-dithiobis(sulfosuccinimidyl propionate) (DTSSP, Thermo Fisher Scientific) No statistical method was used to pre-specified sample size. Sample size was determined on the basis of control samples and the experimental samples. We have basically used the data from at least two or three independent experiments when necessary. The P values results from statistical analyses suggested that the samples sizes in our study are sufficient. With regard to binding assay, the sample size was small, because it is difficult to get the patient numbers needed. Still the P values results from statistical analyses suggested that the samples sizes in our study are sufficient, although an extended study is required to confirm the findings .
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Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All samples were assigned to groups randomly.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to allocation during data collection and analyses. 
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Statistical analyses were performed with the GraphPad Prism 7 software (GraphPad), the R software (the R Foundation) and Excel (Microsoft). Flow cytometric analyses were performed with the FlowJo analysis software (FlowJo). Electrophoretic analyses were performed with the Image Gauge (Millipore). Mass analyses were performed with the Mascot (Matrix Science).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
Each cell line was regularly tested for mycoplasma contamination by PCR.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Not applicable.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Not applicable, because our study does not include animal studies.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
For blood samples from Thai patients , clinical P. falciparum isolates were collected from patients living in the Mae Sariang district, Mae Hong Son Province in Thailand. For binding assay, blood samples from children, aged 1 month to 5 years, were collected in Tanzania. For serological analyses, plasma samples from children and adults, aged 6 months to 60 years, were collected in Mkokola, Tanzania.
